Katsuhito Miyazawa

Prof. Dr. Katsuhito Miyazawa

Kanazawa medical university
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2014 in Oncology Letters
Verified
Journal Article
Open access
PDF file
KMKatsuhito Miyazawa
Katsuhito Miyazawa
TTTakuji Tanaka
Takuji Tanaka
DNDan Nakai
Dan Nakai
NMNobuyo Morita
Nobuyo Morita
KSKoji Suzuki
Koji Suzuki
Cancer stem cells (CSCs) have been identified in a variety of cancer types, including prostate cancer. The aim of the present study was to evaluate the immunohistochemical expression of NANOG, octamer 4 (OCT4), cluster of differentiation 133 (CD133) and NESTIN, which are all CSC markers, and assess their function in prostate carcinogenesis. A total of 114 patients were referred to the Kanazawa Medical University Hospital (Uchinada, Japan) having presented with elevated serum prostate‑specific antigen levels and/or abnormal digital rectal examinations, and underwent transrectal ultrasound sonography guided eight core biopsies. The prostate pathological specimens were re‑evaluated for selection in this study. When specimens were diagnosed as prostate cancer, immunohistochemical analysis of the four different stem cell markers (NANOG, OCT4, CD133 and NESTIN) and hypoxia‑inducible factor (HIF)‑1α was performed. Prostate cancer was found in 38 cases (33.3%), while the other patients had benign prostate hyperplasia with prostatitis. All prostate cancers were histopathologically identified as adenocarcinomas of various grades, and cancer cells and intraepithelial neoplasia (high grade) were immunohistochemically shown to express NANOG and OCT4, but not CD133 and NESTIN. The intensity of NANOG expression was much greater than that of OCT4, and the positivity and intensity of the four stem cell markers, including NANOG, were elevated with high Gleason scores. A significant correlation was observed between the NANOG‑ and HIF‑1α‑positive regions. The CSC markers, in particular OCT4 and NANOG, were immunohistochemically expressed in prostate cancers. Furthermore, HIF‑1α expression may affect NANOG and/or OCT4 expression. The findings of the current study suggested that NANOG expression may be a biomarker for the diagnosis of prostate cancer, and the coexpression of NANOG and HIF‑1α may be involved in prostate carcinogenesis.

9 December 2008 in Urological Research
Verified
Journal Article
Closed access
PDF file
KMKatsuhito Miyazawa
Katsuhito Miyazawa
KAKinue Aihara
Kinue Aihara
RIRyosuke Ikeda
Ryosuke Ikeda
MMManabu T. Moriyama
Manabu T. Moriyama
KSKoji Suzuki
Koji Suzuki

3 July 2004 in Urological Research
Verified
Journal Article
Closed access
PDF file
KMKatsuhito Miyazawa
Katsuhito Miyazawa
KSKoji Suzuki
Koji Suzuki
RIRyosuke Ikeda
Ryosuke Ikeda
MMManabu T Moriyama
Manabu T Moriyama
YUYoshimichi Ueda
Yoshimichi Ueda
SKShogo Katsuda
Shogo Katsuda

14 July 2012 in Japanese Journal of Radiology
Verified
Journal Article
Closed access
PDF file
KMKatsuhito Miyazawa
Katsuhito Miyazawa
MMMunetaka Matoba
Munetaka Matoba
HMHiroshi Minato
Hiroshi Minato
NMNobuyo Morita
Nobuyo Morita
ICIppei Chikazawa
Ippei Chikazawa
KSKoji Suzuki
Koji Suzuki

12 July 2023 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
CUChiharuko Ushimoto
Chiharuko Ushimoto
SSShigeru Sugiki
Shigeru Sugiki
KKKenshirou Kunii
Kenshirou Kunii
SIShinya Inoue
Shinya Inoue
EKEriko Kuroda
Eriko Kuroda
KMKatsuhito Miyazawa
Katsuhito Miyazawa

Verified
Journal Article
Open access
PDF file
Takanobu TakataTakanobu Takata
Takanobu Takata
SIShinya Inoue
Shinya Inoue
TMTogen Masauji
Togen Masauji
KMKatsuhito Miyazawa
Katsuhito Miyazawa
YMYoshinaru Motoo
Yoshinaru Motoo
Cardiomyocyte dysfunction and cardiovascular diseases (CVDs) can be classified as ischemic or non-ischemic. We consider the induction of cardiac tissue dysfunction by intracellular advanced glycation end-products (AGEs) in cardiomyocytes as a novel type of non-ischemic CVD. Various types of AGEs can be generated from saccharides (glucose and fructose) and their intermediate/non-enzymatic reaction byproducts. Recently, certain types of AGEs (Nε-carboxymethyl-lycine [CML], 2-ammnonio-6-[4-(hydroxymetyl)-3-oxidopyridinium-1-yl]-hexanoate-lysine [4-hydroxymethyl-OP-lysine, hydroxymethyl-OP-lysine], and Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine [MG-H1]) were identified and quantified in the ryanodine receptor 2 (RyR2) and F-actin–tropomyosin filament in the cardiomyocytes of mice or patients with diabetes and/or heart failure. Under these conditions, the excessive leakage of Ca2+ from glycated RyR2 and reduced contractile force from glycated F-actin–tropomyosin filaments induce cardiomyocyte dysfunction. CVDs are included in lifestyle-related diseases (LSRDs), which ancient people recognized and prevented using traditional medicines (e.g., Kampo medicines). Various natural compounds, such as quercetin, curcumin, and epigallocatechin-3-gallate, in these drugs can inhibit the generation of intracellular AGEs through mechanisms such as the carbonyl trap effect and glyoxalase 1 activation, potentially preventing CVDs caused by intracellular AGEs, such as CML, hydroxymethyl-OP, and MG-H1. These investigations showed that bioactive herbal extracts obtained from traditional medicine treatments may contain compounds that prevent CVDs.